Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction (MARBLE)
Postoperative Delirium, Postoperative Cognitive Dysfunction
About this trial
This is an interventional prevention trial for Postoperative Delirium focused on measuring Delirium, Aging, Elderly, Postoperative, Cognitive Dysfunction
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 60
- Ability to speak English
- Undergoing non-cardiac, non-neurologic surgical procedures; surgery scheduled to last > 2 hours; due to be admitted to the hospital following surgery
Exclusion Criteria:
- Inmate of a correctional facility
- Scheduled to receive systemic chemotherapy between the time of the two cognitive testing sessions
- Known inability to undergo LPs due to anticoagulant use, severe anxiety, or other clinical contraindication known ahead of time.
- Inappropriate for study inclusion based on the judgement of the principal investigator.
- If a patient undergoes major head trauma that occurs between the times of the two cognitive testing sessions, then they will be withdrawn from the study.
Sites / Locations
- Duke University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
CN-105
Placebo
Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17 Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17 Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17
Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17 Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17 Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17